drugset
drugset / Trial / NCT06464939

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

NCT06464939 ↗

Phase 2 Completed 120 enrolled HysensBio Co., Ltd The Forsyth Institute · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.

Timeline

Start
2024-10-08
Primary completion
2025-12-22
Completion
2025-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject KH001 Unknown — Topical

Indications

dentin sensitivity